Somatic activating ARAF mutations in Langerhans cell histiocytosis

Blood

Volumn 123, Issue 20, 2014, Pages 3152-3155

  Nelson, David S ^a   Quispel, Willemijn ^b   Badalian Very, Gayane ^a,c   Van Halteren, Astrid G S ^b   Van Bos, Cor Den ^d   Bovée, Judith V M G ^b   Tian, Sara Y ^a   Van Hummelen, Paul ^a   Ducar, Matthew ^a   MacConaill, Laura E ^a,c   Egeler, R Maarten ^e   Rollins, Barrett J ^a,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HARVARD MEDICAL SCHOOL   (United States)

^d EMMA CHILDREN S HOSPITAL   (Netherlands)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

A RAF KINASE; B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; VEMURAFENIB;

ALLELE; ANIMAL CELL; ARTICLE; CASE REPORT; CELL ISOLATION; CELL TRANSFORMATION; CHILD; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; EXOME; FIBROBLAST; GENE ACTIVITY; GENE SEQUENCE; HISTIOCYTE; HUMAN; HUMAN CELL; IN VITRO STUDY; LANGERHANS CELL; LANGERHANS CELL HISTIOCYTOSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; SOMATIC MUTATION; WILD TYPE;

ANIMALS; BALB 3T3 CELLS; ENZYME ACTIVATION; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; LANGERHANS CELLS; MAP KINASE SIGNALING SYSTEM; MICE; MUTATION; PROTO-ONCOGENE PROTEINS A-RAF; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84901424838     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-06-511139     Document Type: Article

References (23)

1. Badalian-Very G, Vergilio JA, Fleming M, Rollins BJ. Pathogenesis of Langerhans cell histiocytosis. Annu Rev Pathol. 2013;8:1-20.
2. Bechan GI, Egeler RM, Arceci RJ. Biology of Langerhans cells and Langerhans cell histiocytosis. Int Rev Cytol. 2006;254:1-43. (Pubitemid 44828726)
3. Egeler RM, van Halteren AG, Hogendoorn PC, Laman JD, Leenen PJ. Langerhans cell histiocytosis: fascinating dynamics of the dendritic cell-macrophage lineage. Immunol Rev. 2010;234(1):213-232.
4. Gadner H, Minkov M, Grois N, et al Histiocyte Society. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013;121(25):5006-5014.
5. Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116(11):1919-1923.
6. Kansal R, Quintanilla-Martinez L, Datta V, Lopategui J, Garshfield G, Nathwani BN. Identification of the V600D mutation in Exon 15 of the BRAF oncogene in congenital, benign langerhans cell histiocytosis. Genes Chromosomes Cancer. 2013;52(1):99-106.
7. Satoh T, Smith A, Sarde A, et al. B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease. PLoS ONE. 2012;7(4):e33891.
8. Sahm F, Capper D, Preusser M, et al. BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood. 2012;120(12):e28-e34.
9. Haroche J, Cohen-Aubart F, Emile JF, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013;121(9):1495-1500.
10. Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012;120(13):2700-2703.
11. DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43(5):491-498.
12. Cibulskis K, Lawrence MS, Carter SL, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31(3):213-219.
13. Marais R, Light Y, Paterson HF, Mason CS, Marshall CJ. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem. 1997;272(7):4378-4383. (Pubitemid 27078513)
14. Thomas RK, Baker AC, Debiasi RM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007;39(3):347-351. (Pubitemid 46328493)
15. Fransén K, Klintenäs M, Osterström A, Dimberg J, Monstein HJ, Söderkvist P. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis. 2004;25(4):527-533. (Pubitemid 38528645)
16. Lee JW, Soung YH, Kim SY, et al. Mutational analysis of the ARAF gene in human cancers. APMIS. 2005;113(1):54-57. (Pubitemid 40278791)
17. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature. 2007;446(7132):153-158. (Pubitemid 46398669)
18. Rebocho AP, Marais R. ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers. Oncogene. 2012.
19. Emuss V, Garnett M, Mason C, Marais R. Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. Cancer Res. 2005;65(21):9719-9726. (Pubitemid 41541448)
20. Baljuls A, Mueller T, Drexler HC, Hekman M, Rapp UR. Unique N-region determines low basal activity and limited inducibility of A-RAF kinase: the role of N-region in the evolutionary divergence of RAF kinase function in vertebrates. J Biol Chem. 2007;282(36):26575-26590. (Pubitemid 47443821)
21. Leicht DT, Balan V, Kaplun A, et al. Raf kinases: function, regulation and role in human cancer. Biochim Biophys Acta. 2007;1773(8):1196-1212. (Pubitemid 47161035)
22. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464(7287):427-430.
23. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809-819.